Skip to main content
. 2018 Jan 18;9(2):33. doi: 10.1038/s41419-017-0040-5

Fig. 2. DOT1L enzyme inhibition enhances OC fusion and resorption ability.

Fig. 2

a RAW264.7 cells pretreated with DMSO or the indicated concentrations of DOT1L inhibitors (EPZ5676 and EPZ004777) and stimulated with RANKL for 60 h. OCs were fixed and stained for TRAP. b–d OC number and surface area measurement according to TRAP staining results shown in a. e Bone resorption assay: OCs were treated with DOT1L inhibitor or DMSO for 5 days in osteoassay plates. Representative images of toluidine blue staining are shown. f Percentage of resorption area relative to the total area of osteoassay plates calculated on the basis of staining results shown in e. Experimental data are expressed as mean ± standard deviation. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, two-tailed unpaired t-test, compared with the DMSO treatment. DMSO: dimethyl sulfoxide.